Dinapar AQ 75 mg / ml 1ml 5's injection

The instruction for medical use of DINAPAR AQ medicine the Trade name of DINAPAR AQ the International unlicensed name Diclofenac Dosage Form Solution for injections, 75 mg/ml Structure contains In one ampoule (1 ml) 75 mg of diclofenac of sodium Excipients: benzyl alcohol, dinatrium edetat, anhydrous sodium sulfite, dihydropotassium phosphate, sodium hydroxide, glikofurol and water for injections the Description Transparent solution from colourless till slightly yellowish color Pharmacotherapeutic group Drugs for treatment of a musculoskeletal sisitema. Protivovospalitelyy and antirheumatic drugs. Non-steroidal anti-inflammatory drugs. Acetic acid derivatives. Diclofenac. The ATX M01AB05 code the Pharmacological Pharmacokinetics Later properties of intramuscular introduction of 75 mg of diclofenac its absorption begins immediately. The maximum concentration in plasma which average value is about 2.5 mkg/ml (8 µmol/l) is reached approximately in 20 minutes. Right after its achievement the fast decrease in concentration of drug in plasma is observed. The amount of the soaking-up active agent is in linear dependence on drug dose size. Area size under a curve concentration time (AUC) after intramuscular administration of drug DINAPAR AQ is approximately twice more, than after its oral or rectal administration as in the last cases about a half of amount of diclofenac is metabolized at the first passing through a liver. After repeated use of drug the pharmacokinetic indicators do not change. On condition of observance of the recommended intervals between administrations of drug of cumulation it is not noted. Linking with serum proteins makes 99.7%, it happens, mainly to albumine (99.4%). The approximate volume of distribution is 0.12-0.17 l/kg. Diclofenac gets into synovial fluid where its maximum concentration is reached at 2-4 o'clock later, than in blood plasma. Approximate elimination half-life makes 3-6 hours of synovial fluid. In 2 hours after achievement of the maximum concentration in plasma the concentration of diclofenac in synovial fluid is higher, than in plasma, and its values remain higher till 12 o'clock. Metabolism of diclofenac is carried out partially by a glyukuronization of not changed molecule, but, mainly, by means of a single and repeated metoksilirovaniye that leads to formation of several phenolic metabolites (3 '-hydroxies-4 '-hydroxy, 5' - hydroxy, 4', 5-digidroksi- and 3 '-hydroxies-4 '-metoksidiklofenaka), the majority of which turns into glyukuronidny conjugates. Two of these phenolic a metabolite are biologically active, but in much smaller degree, than diclofenac. The general system plasma clearance of diclofenac is 263±56 ml/min. Final elimination half-life makes 1-2 hours. Elimination half-life of 4 metabolites, including two pharmacological active, is also short and makes 1-3 hours. One of metabolites, 3 '-hydroxies-4 '-metoksi-diclofenac, has longer elimination half-life, however this metabolite is completely inactive. About 60% of the accepted dose of drug are removed with urine in the form of glucuronic conjugates of not changed active agent and also in the form of metabolites, the majority of which is represented by glucuronic conjugates. In not changed look less than 1% of diclofenac are removed. The rest of the accepted dose of drug is removed in the form of metabolites with bile, with a stake and urine. The pharmacokinetics at separate groups of patients At some patients of advanced age 15-minute intravenous infusion resulted in concentration, higher for 50%, in plasma, than it was observed at young healthy faces. At patients with a renal failure when prescribing drug DINAPAR AQ in usual single doses of accumulation of diclofenac it was not noted. However eventually metabolites are removed with bile. At patients with chronic hepatitis or the compensated cirrhosis the indicators of pharmacokinetics of diclofenac are similar to that at patients without liver diseases. The pharmacodynamics of DINAPAR AQ contains sodium diclofenac, the substance of nonsteroid structure rendering the significant anti-inflammatory, analgetic and febrifugal action. Slowing down of biosynthesis of prostaglandins is considered the main mechanism of effect of diclofenac. Prostaglandins play an important role in genesis of inflammation, pain and fever. In rheumatic diseases the protivospalitelny and analgetic properties of drug DINAPAR AQ provide the clinical effect which is characterized by considerable reduction of expressiveness of such symptoms and complaints as pain at rest and at the movement, morning constraint and a swelling of joints and also function improvement. Diclofenac of sodium does not suppress biosynthesis of proteoglycans of cartilaginous tissue. At the posttraumatic and postoperative inflammatory phenomena of DINAPAR AQ quickly stops pains (both spontaneous, and arising at the movement), reduces inflammatory hypostasis and hypostasis of a postoperative wound. The considerable analgetic effect of drug at a moderate and severe pain syndrome of not rheumatic genesis is revealed. DINAPAR AQ is capable to eliminate pain at primary dysmenorrhea. DINAPAR AQ, besides, has favorable effect on manifestations of attacks of migraine. Indications Intramuscular introduction - aggravation of inflammatory and degenerative forms of rheumatism: the pseudorheumatism ankylosing a spondylitis, an osteoarthritis, a spondylarthritis, a pain syndrome in backbone diseases, extraarticular rheumatism - a bad attack of gout - renal or hepatic gripes - a posttraumatic and postoperative pain syndrome, inflammation and puffiness - heavy attacks of migraine Intravenous infusion - treatment or prevention of postoperative pain in the conditions of a hospital the Route of administration and doses: It is not necessary to use an injection drug DINAPAR AQ more than 2 days in a row. If necessary treatment can be continued by means of drug DINAPAR AQ in tablets or rectal candles. Intramuscular introduction Drug is used at adult patients. The drug is administered intramusculary by a deep injection in rump. When carrying out an intramuscular injection to avoid injury of nerves or other fabrics to the place of an injection (that can lead to muscle weakness, muscular paralysis and a hypesthesia), it is recommended to follow the following rules. The drug should be administered deeply intramusculary in an upper external quadrant of rump, using the aseptic equipment. The dose usually makes 75 mg (contents of 1 ampoule) once a day. In hard cases, as an exception, 2 injections on 75 mg, with an interval in several hours can be carried out (the second injection has to be carried out to opposite rump). As an alternative, one injection of drug a day (75 mg) can be combined with reception of other dosage forms of drug DINAPAR AQ (tablets, rectal candles), at the same time the maximum daily dose makes 150 mg. At migraine attacks the clinical experience is limited to use of one ampoule of 75 mg, the dose is entered after use of suppositories on 75 mg on the same day (if necessary). The general daily dose should not exceed 150 mg in the first day. Intravenous infusion of DINAPAR AQ, solution for injections, it is not necessary to enter in the form of an intravenous bolyusny injection and to apply more than 2 days in a row. Just before the beginning of infusion of drug DINAPAR AQ, depending on its necessary duration, it is necessary to dissolve in 100-500 ml 0.9% of solution of sodium of chloride or 5% of the solution of glucose buffered by the sodium bicarbonate solution for injections (0.5 ml of 8.4% of solution or 1 ml of 4.2%, or the corresponding volume of other concentration) taken from just open container, to add contents of one ampoule of drug DINAPAR AQ to this solution. It is possible to use only transparent solutions. If in solution crystals or a deposit are defined, it cannot be applied to infusion. Two alternative modes of drug dosing of DINAPAR AQ, solution for injections are recommended. For treatment of moderate and heavy postoperative pain of 75 mg it is necessary to enter continuously of 30 minutes till 2 o'clock. If necessary, treatment can be repeated in several hours, but the dose should not exceed 150 mg during any period at 24 o'clock. For prevention of postoperative pain in 15 min.-1 hour after surgical intervention it is necessary to enter a load dose of 25-50 mg, after that it is necessary to perform continuous infusion about 5 mg/hour to the maximum daily dose of 150 mg. The geriatrics (patients at age & gt, 65) Correction of an initial dose is not required for elderly patients. Nevertheless, it is necessary to be careful at use for the weakened elderly patients or for elderly patients with low body weight. The established cardiovascular disease or essential risk factors from a cardiovascular system As a rule, therapy of drug DINAPAR AQ is not recommended to patients with the established cardiovascular disease or an uncontrollable hypertension. If necessary, DINAPAR AQ is appointed to patients with the established cardiovascular disease, an uncontrollable hypertension, or essential risk factors of a cardiovascular disease only after thorough examination and only within daily doses ≤ 100 mg in case of therapy lasting over 4 weeks. Patients with impaired renal function of DINAPAR AQ it is contraindicated to patients with a renal failure (SKF & lt, 15 ml/min. / 1.73м2). In a type of lack of specialized researches among patients with impaired renal function, the recommendation about special correction of a dose cannot be provided. It is recommended to be careful at use of drug DINAPAR AQ for patients with a renal failure. Patients from the liver of DINAPAR AQ broken by function it is contraindicated to patients with a liver failure. In a type of lack of specialized researches among patients from the liver broken by function, the recommendation about special correction of a dose cannot be provided. It is recommended to be careful at use of drug DINAPAR AQ for patients with a slight and moderate abnormal liver function. Side effects the Following undesirable effects include the phenomena connected with administration of drug DINAPAR AQ, solution for injections and/or other dosage forms of diclofenac in the conditions of short-term and prolonged use. Often (≥ 1/100 to & lt, 1/10) - a headache, dizziness - vertigo - nausea, vomiting, diarrhea, dyspepsia, an abdominal pain, a meteorism, hyporexia - increase in level of transaminases - a liquid delay, hypostases, arterial hypertension - rash - reaction in the place of an injection, pain in the place of an injection, hardening in the place of an injection Infrequently (≥1/100 to & lt, 1/1000) - a myocardial infarction, heart failure, a cardiopalmus, a stethalgia Seldom (≥ 1/1000 to & lt, 1/10000) - hypersensitivity, anaphylactic and pseudoanaphylactic reactions (including arterial hypotension and shock) - drowsiness - asthma (including dispnoe) - gastritis, gastrointestinal bleedings, vomiting with blood impurity, hemorrhagic diarrhea, a melena, ulcer of stomach or intestines (with bleeding or without it, perforation) - hepatitis, jaundice, an abnormal liver function - urticaria - hypostasis, necrosis in the place of an injection Is very rare (& lt, 1/10000) - abscess in the place of an injection - thrombocytopenia, a leukopenia, anemia (including hemolytic and aplastic anemia), an agranulocytosis - a Quincke's disease (including a face edema) - a disorientation, a depression, insomnia, nightmares, irritability, mental disorders - paresthesia, disturbance of memory, a spasm, uneasiness, a tremor, aseptic meningitis, disorder of sense of taste, an acute disorder of cerebral circulation - a disorder of vision, illegibility of sight, a diplopia - a ring in ears, a hearing disorder - arterial hypertension, a vasculitis - a pneumonitis - colitis (including hemorrhagic colitis and exacerbation of ulcer colitis or Crohn's disease), a constipation, stomatitis, a glossitis, disorders from a gullet, diafragmopodobny strictures of intestines, pancreatitis - fulminantny hepatitis, gepatonekroz, a liver failure - bullous dermatitis, eczema, an erythema, a multiformny erythema, Stephens-Johnson's syndrome, a toxic epidermal necrolysis (Lyell's disease), exfoliative dermatitis, an alopecia, reaction of photosensitivity, purple, purple of Genokha-Shenleyn, an itching - an acute renal failure, a hamaturia, a proteinuria, a nephrotic syndrome, tubulointerstitsialny nephrite, renal papillary necrosis Diclofenac, especially in high doses (150 mg/days) and at prolonged use, can increase risk of developing of an arterial thrombembolia (for example, a myocardial infarction or a stroke). Visual effects Visual disturbances, such as disorder of vision, turbidity of sight or a diplopia, apparently, are effects of class NPVP and, as a rule, are reversible at the treatment termination. The probable origins of visual disturbances is the inhibition of synthesis of prostaglandins and other related connections which change regulation of a blood-groove in a retina that leads to potential changes in sight. If such symptoms arise during treatment by diclofenac, it is possible to perform ophthalmologic examination to exclude other reasons. Contraindications - the known hypersensitivity to active ingredient, sodium metabisulphite or to any other components of drug - existence in the anamnesis of a bronchospasm, urticaria, acute rhinitis, nasal polyps or allergic symptoms after intake of acetylsalicylic acid or others nonsteroid anti-inflammatory drugs (NPVP) - the III trimester of pregnancy and the period of a lactation - active ulcer of stomach and/or duodenum, bleeding or perforation - a liver failure - a renal failure (SKF & lt, 15 ml/min. / 1.73 sq.m) - heavy heart failure - inflammatory bowel diseases (for example, Crohn's disease or ulcer colitis) - patients with high risk of developing postoperative bleedings, disturbances of a hemostasis and fibrillation, risk of hemopoietic disturbances or cerebrovascular bleedings - treatment of postoperative pain after operation of coronary shunting (or uses of the cardiopulmonary bypass) - children's and teenage age up to 18 years Medicinal interactions CYP2C9 Inhibitors: It is recommended to be careful at joint prescribing of diclofenac with CYP2C9 inhibitors (such as vorikonazol) which can lead to significant increase in peak of concentration in blood plasma and exposure of diclofenac. Lithium, DINAPAR AQ digoxin can increase concentration of lithium and digoxin in blood plasma. Monitoring of level of lithium and digoxin in blood serum is recommended. Diuretics and antihypertensive drugs: As well as for other NPVP, simultaneous use of diclofenac with diuretics or antihypertensive drugs (for example, beta-blockers, inhibitors of angiotensin-converting enzyme (APF)) can lead to decrease in their antihypertensive influence. Patients, especially elderly people, have to be under careful control of arterial blood pressure. Patients have to receive appropriate hydration, also monitoring of renal function after the beginning of the accompanying therapy and on a regular basis after it, especially concerning diuretics and APF inhibitors, owing to increase in risk of nephrotoxicity is recommended. The accompanying treatment by drugs of potassium can be connected with increase in level of potassium in blood serum that demands stay of patients under constant control. Cyclosporine and takrolimus Influence of NPVP on synthesis of prostaglandins in kidneys can increase nephrotoxicity of cyclosporine and a takrolimus. Diclofenac should be applied in lower doses, than at patients who do not receive cyclosporine or takrolimus. The drugs causing a hyperpotassemia the Accompanying treatment by kaliysberegayushchy diuretics, cyclosporine takrolimusy or Trimethoprimum can increase serumal levels of potassium. It is necessary to control often potassium levels in blood serum. Antibacterial agents - derivatives of a hinolon Are available separate messages about development of spasms in the patients receiving are at the same time derivative
a hinolona and NPVP. Other non-steroidal anti-inflammatory drugs (NPVP) and corticosteroids Simultaneous system use of NPVP or corticosteroids with diclofenac can increase the frequency of emergence of the undesirable phenomena from digestive tract. Anticoagulants and antitrombotichesky means Exist messages about increase in risk of bleedings at the patients accepting at the same time DINAPAR AQ and anticoagulants. In case of such combination of medicines the careful and regular observation of patients is recommended. Selective Serotonin Reuptake Inhibitors (SSRI): Co-administration of system NPVP and SIOZS can increase risk of gastrointestinal bleeding. Antidiabetic drugs Perhaps simultaneous use of drug DINAPAR AQ and antidiabetic drugs, at the same time the efficiency of the last does not change. Separate messages about development in such cases are known, to both a hypoglycemia, and a hyperglycemia that caused need of change of a dose of glucose-lowering drugs during use of drug DINAPAR AQ. There were also separate messages about a metabolic acidosis when diclofenac was applied along with metformin, especially at patients with earlier existing renal failure. Kolestipol and holestiramin Simultaneous use of diclofenac and a kolestipol or holestiramin reduces diclofenac absorption approximately by 30% and 60%, respectively. The drugs should be taken at an interval of several hours. Methotrexate It is necessary to be careful when assigning NPVP less than in 24 hours prior to or after reception of a methotrexate as in such cases the concentration of a methotrexate in blood can increase and amplify its toxic action. The inductors CYP2C9 It is recommended to be careful at simultaneous use of diclofenac with the inductors CYP2C9 (such as rifampicin) as it can lead to considerable decrease in concentration in plasma and to diclofenac influence. Phenytoinum Is recommended monitoring of concentration of Phenytoinum in plasma at simultaneous use with diclofenac because of possible increase in Phenytoinum exposure. Pharmaceutical incompatibility it is not necessary to mix the solution of drug DINAPAR AQ which is contained in ampoules with solutions of other medicines for injections. Special instructions: The general It is necessary to avoid use of drug DINAPAR AQ with system NPVP, including selection inhibitors of cyclooxygenase-2, in a type of lack of any synergy advantage and a possibility of development of additional side effects. It is necessary to be careful when prescribing drug to elderly people. With poor health and for patients with a low indicator of body weight it is recommended to apply the lowest effective doses to people of advanced age. Asthma in the anamnesis At patients with bronchial asthma, seasonal allergic rhinitis, a rhinedema (nasal polyps), with the chronic obstructive diseases of lungs or persistent infections of airways (which are especially connected with allergic, similar to rhinitises, symptoms) more often than others have reactions to NPVP similar to exacerbation of asthma, a Quincke's edema or urticaria. Special measures (readiness for rendering emergency aid) are recommended to such patients. It also concerns patients with an allergy to other substances, for example, with skin reactions, an itching or urticaria. Special cautions are recommended in case DINAPAR AQ is applied parenterally to patients with bronchial asthma as symptoms can become aggravated. Influence on digestive system As well as at use of other NPVP, when prescribing drug DINAPAR AQ to patients with the symptoms demonstrating disturbances from the digestive system (DS) with presence of stomach ulcer or intestines, bleeding or perforation in the anamnesis, is obligatory medical observation and extra care. The risk of developing of bleeding in digestive tract increases with increase in a dose of drug at patients with an ulcer in the anamnesis, especially with complications in the form of bleeding or perforation, and at people of advanced age. If at use of drug DINAPAR AQ for patients there are gastrointestinal bleedings or an ulceration, treatment should be stopped. To reduce risk of toxic impact on PS at patients with an ulcer in the anamnesis, especially with complications in the form of bleeding or perforation and at people of advanced age, treatment is begun and supported by low effective doses. For such patients and also the patients needing the accompanying use of the medicines containing low doses of acetylsalicylic acid or other medicines which presumably increase risk of undesirable impact on PS it is necessary to consider a question of use of combination therapy using protective equipment (for example, inhibitors of the proton pump or a mizoprostol). Patients with gastrointestinal toxicity in the anamnesis, especially advanced age, have to report about any unusual abdominal symptoms (especially bleedings in PS). Cautions are also necessary for the patients receiving the accompanying drugs which can increase risk of developing an ulcer or bleeding, such as system corticosteroids, anticoagulants, antitrombotichesky means or selective serotonin reuptake inhibitors. DINAPAR AQ needs to appoint with care the patient in whose anamnesis there are inflammatory bowel diseases, such as Crohn's disease or nonspecific ulcer colitis and to establish careful medical control and the appropriate preventive measures, in connection with potential aggravation. Influence on a liver Careful medical control is necessary in case DINAPAR AQ is appointed to patients with an abnormal liver function as the condition of such patients can become aggravated. As well as at use of other NPVP, the level of one and more hepatic enzymes can increase. It was observed very often at use of diclofenac in researches (approximately at 15% of patients), but very seldom was followed by manifestation of clinical symptoms. Increase to limits was in most cases observed. Frequent (in 2.5% of cases) the revealed increase was moderate (from ≥3 to & lt, 8 times in comparison with the upper bound of norm) whereas the frequency of the significant increase (≥8 times in comparison with the upper bound of norm) remained about 1%. In above-mentioned clinical trials the increase in level of liver enzymes was followed by clinical manifestations of damage of a liver in 0.5% of cases. Increase in levels of enzymes usually was reversible after the termination of administration of drug. During long-term treatment, regular control of function of a liver is appointed drug DINAPAR AQ (tablets or suppositories). If abnormal liver functions remain or worsen and also if the symptoms connected with the progressing liver diseases or other manifestations are observed (for example, an eosinophilia, rash), use of drug DINAPAR AQ should be stopped. The course of diseases, such as hepatitis, can pass without prodromal symptoms. The care is necessary in case DINAPAR AQ is applied at patients with a hepatic porphyria because of the probability of provocation of an attack. Influence on kidneys As at treatment of NPVP was reported about a delay of liquid, arterial hypertension and hypostasis, monitoring of renal function by the patient with dysfunction of heart or kidneys (including with a functional renal failure against the background of a hypovolemia, a nephrotic syndrome, a lupoid nephropathy and dekompensirovanny cirrhosis), arterial hypertension in the anamnesis is recommended, to the patients of advanced age, patients receiving therapy by diuretics or drugs which significantly influence function of kidneys, and to patients with significant decrease in extracellular volume of liquid for any reason, for example, to or after serious surgical intervention. The termination of therapy of NPVP usually leads to return to a state which preceded treatment. Skin reactions Due to the use of NPVP, including DINAPAR AQ, it was very seldom reported about heavy, up to fatal, skin reactions, including exfoliative dermatitis, Stephens's syndrome — Johnson and a toxic epidermal necrolysis. The highest risk of these reactions exists at the beginning of therapy, and development of these reactions is noted in most cases in the first month of treatment. DINAPAR AQ should be cancelled at the first manifestations of skin rash, the centers of injury of a mucous membrane or any other manifestations of hypersensitivity. As well as in a case with other NPVP, seldom or never with diclofenac there can be allergic reactions, including anaphylactic/anaphylactoid reactions, in the absence of former exposure to drug. Influence on hematologic indicators At prolonged use of drug, as well as other NPVP, is recommended blood test monitoring. As well as other NPVP, DINAPAR AQ can temporarily inhibit aggregation of thrombocytes. It is necessary to watch carefully patients with disturbances of a hemostasis. Cardiovascular effects Treatment of NPVP, including diclofenac, especially in high doses and during the long period, can be connected with small increase in risk of serious cardiovascular cases of thrombosis (including a myocardial infarction and a stroke). At the patients accepting NPVP, especially at patients with cardiovascular risk factors it is necessary to apply a minimal effective dose to minimizing of potential risk of collateral cardiovascular complications at the smallest admissible duration of treatment. As a rule, therapy by drug DINAPAR AQ is not recommended to patients with the established cardiovascular disease (stagnant heart failure, the established coronary heart disease, a peripheral arterial disease) or an uncontrollable hypertension. If necessary, DINAPAR AQ is appointed to patients with the established cardiovascular disease, an uncontrollable hypertension, or essential risk factors of a cardiovascular disease (hypertensia, a lipidemia, diabetes and smoking) only after thorough examination and only within daily doses ≤ 100 mg in case of therapy lasting over 4 weeks. In a type of possible increase in risks from diclofenac from a cardiovascular system as a result of a dosage and duration of exposure, it is necessary to use a minimal effective dose during the minimum period. It is required to carry out periodically the repeated assessment of need for relief of symptoms and the response to therapy of the patient, in particular lasting therapy over 4 weeks. Patients have to show vigilance concerning manifestations and symptoms of the heavy arteriotrombotichesky phenomena (for example, a stethalgia, short wind, weakness, the illegible speech) which can arise without the warning symptoms. Patients have to be instructed about need of urgent visit of the therapist for similar cases. Can lead excipients of the drug Sodium metabisulphite in solution for injections to the isolated heavy reaction of hypersensitivity and a bronchospasm. Masking of manifestation of infectious diseases of DINAPAR AQ, as well as other NPVP, thanks to the pharmakodinamichesky properties, can mask manifestations and symptoms of infectious diseases. Pregnancy and the period of a lactation Inhibition of synthesis of prostaglandins can negatively influence a course of pregnancy and/or development of an embryo or fruit. The data obtained in epidemiological researches confirm the increased risk of a miscarriage and also development of heart diseases and a gastroshizisa after use of inhibitors of synthesis of prostaglandins in early pregnancy. It is considered that the risk increases with increase in a dose and increase in duration of therapy. There are data that use of inhibitors of synthesis of prostaglandins leads to increase in quantity pre- and post-implantation losses and cases of embriofetalny lethality. Besides, noted the increased frequency of various malformations, including cardiovascular. It is not necessary to appoint diclofenac at the first two trimesters of pregnancy, except for emergency cases. If diclofenac is accepted by the woman who tries to become pregnant or is in I or II trimester of pregnancy, the dose has to be as low as possible, and treatment duration — as it is possible well. Diclofenac is contraindicated in the III trimester of pregnancy. All inhibitors of synthesis of prostaglandins can: to cause such risks for a fruit: - toxic damage of heart and a respiratory system (with premature closing of an arterial channel and development of pulmonary hypertensia), - a renal failure which can progress to a renal failure which is followed oligogidramniozy, to cause such risks for mother and the child: - lengthening of a bleeding time and influence on inhibition of aggregation of thrombocytes, even at use in low doses, - inhibition of reductions of a uterus that leads to a delay and lengthening of childbirth. Diclofenac gets into breast milk in a small amount. To avoid undesirable influence on the baby, DINAPAR AQ should not be applied during feeding by a breast. If treatment is extremely necessary, it is necessary to stop feeding by a breast and to transfer the child to artificial feeding. The fertility of DINAPAR AQ can affect fertility of the woman. Drug is not recommended to the women planning pregnancy. The women having complications with fertilization or those which underwent inspection owing to an infertilnost have to stop use of drug DINAPAR AQ. Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms Patients at whom during the DINAPAR AQ drug treatment disorders of vision, dizziness, drowsiness or other disturbances are observed from the central nervous system have to abstain from control of motor transport and work with mechanisms. Overdose: Symptoms: vomiting, gastrointestinal bleeding, diarrhea, dizziness, a ring in ears or spasms. In case of a serious poisoning the acute renal failure and damage of a liver is possible. Treatment: the supporting measures and symptomatic treatment which are necessary for elimination of such complications as arterial hypotension, a renal failure, spasms, gastrointestinal disturbances and respiratory depression. Special measures, such as artificial diuresis, dialysis or hemoperfusion, cannot guarantee removal of NPVP owing to their high linking with proteins of blood plasma and intensive metabolism. Form of release and packing: On 1.0 ml in glass ampoules. On 5 ampoules in plastic strip packaging. On 1 plastic strip packaging together with the instruction for use in the state and Russian languages place in a pack from cardboard. To Store storage conditions at a temperature not above 30 °C. Not to freeze. To store out of children's reach the Period of storage 2 years not to apply after the expiry date specified on packing. Prescription status According to the prescription of Proizvoditel Troykaa Pharmasyyutikals Limited, S-1, Dekhradun-248197, Utaranchal, India the Owner
to Develop